Progenics Extends Agreement With Pfizer for Relistor Commercialization

Progenics Pharmaceuticals, Inc. Monday announced it has extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to continue Wyeth’s commercialization of Relistor (methylnaltrexone bromide) Subcutaneous Injection in the United States through at least December 31, 2010.
Earth Times